{"analyses":[{"ciLowerLimit":"0.71","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"2.34","estimateComment":"Reference level = Chemoradiation","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4075","paramType":"Hazard Ratio (HR)","paramValue":"1.29","statisticalComment":"Two-side significance level = 0.05","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.7","upperLimit":"26.6","value":"17.2"},{"groupId":"OG001","lowerLimit":"12.4","upperLimit":"30.2","value":"20.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"86"}],"units":"Participants"}],"description":"Local-regional progression (LRP) is defined as progression within the planned treatment volume (PTV) or outside the PTV but within the same lobe(s) of the lung as the primary tumor or in regional lymph nodes. Progression is defined as change in a known lesion(s) meeting one of the following criteria: \\[1\\] ≥ 20% increase in the sum of the longest diameter of target lesions such that the absolute increase must be \\> 5 mm. \\[2\\] Appearance of ≥1 new lesions. LRP time is defined as time from randomization to the date of first LRP, death without LRP (competing risk), or last known follow-up (censored). LRP rates are estimated using the cumulative incidence method. The protocol specifies that the distributions of failure times be compared between the arms, which is reported in the statistical analysis results. One-year rates are provided. Analysis occurred after 102 LRP events were reported.","dispersionType":"95% Confidence Interval","groups":[{"description":"60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin","id":"OG000","title":"Chemoradiation"},{"description":"Metformin plus 60 Gy Radiation therapy with concurrent paclitaxel and carboplatin followed by consolidation paclitaxel and carboplatin","id":"OG001","title":"Metformin + Chemoradiation"}],"paramType":"NUMBER","populationDescription":"Eligible participants","reportingStatus":"POSTED","timeFrame":"From randomization to last follow-up. Maximum follow-up at time of analysis was 47.2 months.","title":"Percentage of Participants With Local-regional Progression","type":"SECONDARY","unitOfMeasure":"percentage of participants"}